Document is current

Article History

Received: 16 March 2026

Accepted: 11 June 2026

First Online: 26 June 2026

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was approved by the Ethics review authority of Sweden.

: All participants gave written informed consent to participate in the study.

: MZF, MB, KC, OA, AW, JE, GA,IP,KT, WT,AB, NA, and NB have nothing to declare. AN has served as consultant for AG Lundbeck AB, Hoffmann La Roche, AVVA Pharmaceuticals, given lectures for Hoffman La Roche and Astra Zeneca and served on the advisory board for Dementia Platform UK. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of CERimmune Therapeutics (outside submitted work).